CAR T-cell Therapy | Specialty

The OncLive CAR T-cell therapy condition center page is a comprehensive resource for clinical news and expert insights on FDA-approved and investigational CAR T-cell products in hematologic malignancies, specifically acute lymphoblastic leukemia, non-Hodgkin lymphoma, and multiple myeloma. CAR T-cell research in solid tumors is also under exploration. This page features news articles, interviews in written and video format, and podcasts that focus on updates with CAR T-cell therapy and the ongoing research with this type of treatment.

Real-World Data Highlight Efficacy of Ide-cel in Patients With Relapsed/Refractory Multiple Myeloma

September 6th 2022

A single-center study at the Dana-Farber Cancer Institute/Brigham and Women’s Hospital assessed the real-world experience of 20 patients treated with idecabtagene vicleucel with relapsed and refractory multiple myeloma who had exhausted at least 4 lines of prior therapy.

Cilta-cel Induces Favorable MRD Negativity Rates in Heavily Pretreated Myeloma After Prior BCMA-Directed Therapy

August 28th 2022

Ciltacabtagene autoleucel elicited high rates of minimal residual disease negativity in patients with heavily pretreated multiple myeloma who received prior treatment with a BCMA-targeted therapy.

Relma-cel Demonstrates Durable Activity in Relapsed/Refractory LBCL

August 22nd 2022

Relmacabtagene autoleucel elicited durable responses and a high overall survival rate in Chinese patients with relapsed/refractory large B-cell lymphoma, according to 2-year follow-up data from the phase 2 RELIANCE trial.

CAR T-cell Therapy Establishes Prominent Role Across Hematologic Malignancies

August 20th 2022

In recent years, cellular immune therapies such as chimeric antigen receptor T-cell therapy have significantly improved response rates for various hematological malignancies.

CART-ddBCMA Generates Deep Responses in Relapsed/Refractory Multiple Myeloma

August 19th 2022

Matthew J. Frigault, MD, discusses the findings from a phase 1 trial investigating the safety and efficacy of CART-ddBCMA in patients with multiple myeloma in whom all previous lines of treatment had failed and shares additional research opportunities for the CAR T-cell therapy.

Dr. Lin on Patient Eligibility for CAR T-cell Therapy in Hematologic Caners

August 17th 2022

Yi Lin, MD, PhD, discusses patient eligibility for CAR T-cell therapy in hematologic cancers.

FDA Approves Beti-cel for β-thalassemia Requiring Transfusions

August 17th 2022

The FDA has approved betibeglogene autotemcel (Zynteglo) for the treatment of adult and pediatric patients with beta-thalassemia who require regular red blood cell transfusions.

Anbalcabtagene Autoleucel Shows Promise in Relapsed/Refractory LBCL

August 17th 2022

Won Seog Kim, MD, PhD, discusses the potential clinical role of Anbalcabtagene autoleucel in relapsed/refractory diffuse large B-cell lymphoma and the continued evolution of CAR T-cell therapy.

Dr. Shah on How to Address CAR T-Cell Therapy Failure in Hematologic Malignancies

August 16th 2022

Nirav N. Shah, MD, discusses treatment options following CAR T-cell therapy failure in hematologic malignancies.

Ide-cel Produces PFS Benefit Vs Standard Regimens in Relapsed/Refractory Multiple Myeloma

August 10th 2022

Idecabtagene vicleucel elicited a statistically significant improvement in progression-free survival vs standard combination regimens in patients with relapsed/refractory multiple myeloma who had received 2 to 4 lines of prior therapy.

CAR T-cell Therapy CT103A Produces Durable Responses in Relapsed/Refractory Multiple Myeloma

August 3rd 2022

The fully human BCMA-directed CAR T-cell therapy, CT103A, demonstrated deepening efficacy with an acceptable toxicity profile in patients with relapsed or refractory multiple myeloma, according to updated data from the phase 1/2 FUMANBA-1 trial.

FDA Lifts Clinical Hold on KEYNOTE-B79 Trial Evaluating CAR T-cell Therapy CYAD-101 in Metastatic CRC

August 1st 2022

The FDA has lifted a clinical hold on the phase 1b KEYNOTE-B79 trial, which is evaluating the safety and clinical activity of CYAD-101 given concurrently with FOLFOX and followed by pembrolizumab in patients with unresectable metastatic colorectal cancer.

FDA Approval Insights: Liso-Cel in Second-Line Relapsed/Refractory LBCL

July 28th 2022

Dr Ghosh discusses the FDA approval of lisocabtagene maraleucel in large B-cell lymphoma, pivotal efficacy and safety data from the phase 3 TRANSFORM trial (NCT03575351) and the phase 2 TRANSCEND-PILOT-017006 study (NCT03483103), and the effect of the approval on academic and community center practice patterns.

BiTEs, CAR T-Cell Therapy, and ADCs Offer Variety of Lymphoma Treatment Options, But Questions Remain

July 22nd 2022

An influx of bispecific T-cell engagers, CAR T-cell therapies, and antibody-drug conjugates have revolutionized the treatment of hematologic malignancies; however, with several options in the sandbox, accessibility and unexplored clinical questions present challenges for optimal integration of these options into treatment.

Individualized Care Drives Treatment Focus in AML, DLBCL, and CLL

July 11th 2022

Ehab Atallah, MD, explains how patient characteristics influence current treatment strategies in acute myeloid leukemia, how frontline pirtobrutinib may move toward use in chronic lymphocytic leukemia, and the growing evidence favoring CAR T-cell therapy as an effective treatment option in CLL.

Anbalcabtagene Autoleucel Elicits Meaningful Responses in Relapsed/Refractory LBCL

July 8th 2022

The CAR T-cell therapy anbalcabtagene autoleucel generated strong overall response rates in patients with relapsed/refractory large B-cell lymphoma.

Tisa-cel Adds a Potential New ‘Standard-of-Care’ in Third-Line Treatment of Follicular Lymphoma

July 6th 2022

Stephen J. Schuster, MD, discusses the implications of the FDA approval of tisagenlecleucel on the treatment strategy for relapsed/refractory follicular lymphoma and the next steps for tisa-cel.

Brexucabtagene Autoleucel Has Durable Efficacy in B-ALL, Irrespective of Age and Tumor Burden

July 4th 2022

Bijal Shah, MD, MS, discusses the long-term data from the ZUMA-3 trial of brexucabtagene autoleucel in patients with relapsed/refractory B-cell acute lymphoblastic leukemia and spotlighted additional areas ripe for further exploration.

Axi-cel Gains European Approval for Relapsed/Refractory Follicular Lymphoma

June 28th 2022

The European Commission has granted approval to axicabtagene ciloleucel for the treatment of adult patients with relapsed/refractory follicular lymphoma after 3 or more prior lines of systemic therapy.

Cilta-cel Elicits an ORR of 100% in Multiple Myeloma After Early Relapse on Initial Therapy

June 24th 2022

The CAR T-cell therapy ciltacabtagene autoleucel generated a high response rate in patients with multiple myeloma who experienced early clinical relapse or failure to initial therapy.